Sacubitril/Valsartan vs Lifestyle in Hypertrophic Cardiomyopathy
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 168 participants.
Also called NCT03832660
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 168 participants
- Sponsor
- Registry
-
NCT03832660
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Germany, Italy, Serbia, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT03832660. Randomized; no masking; primary purpose treatment. Start 2019-05-03 (actual); primary completion 2022-05-15 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Sacubitril/Valsartan vs Lifestyle in Hypertrophic Cardiomyopathy
- Acronym
- SILICOFCM
- Condition
- Hypertrophic Cardiomyopathy
- Intervention (Behavioral)
- Lifestyle
- Intervention (Drug)
- Sacubitril/Valsartan
- Lead sponsor
- Newcastle University
- Collaborator
- Azienda Ospedaliero-Universitaria Careggi
- Collaborator
- University Hospital Regensburg
- Collaborator
- Institute of Cardiovascular Diseases, Vojvodina
- Collaborator
- University of Belgrade
Record details
- Record id
cardio:ct-nct03832660- Content hash
2cf336780071b948bf774c63292749a2004f4f7524308306abee972197c59e5d